SEC Form 4 · accession 0001179110-18-011179
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anne-Marie Duliege
Officer — EVP & Chief Medical Officer
Period of report
Sep 4, 2018
Accepted (ET)
Sep 6, 2018 · 7:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001034842
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 4, 2018 | M | 16,500 | $2.54 | A | 16,500 | D | |
| Common StockF1,F2 | Sep 4, 2018 | S | 16,500 | $3.5067 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employe Stock Option (right to buy)F3 | $2.54 | Sep 4, 2018 | M | 16,500 | D | — | May 5, 2026 | Common Stock | 16,500 | 383,500 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.
- F2The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $3.50 to $3.53. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the shares sold at each such separate price.
- F3One fourth (1/4th) of the option vests one (1) year from March 7, 2016 and thereafter the balance of the option vests in equal monthly installments over the next thirty-six (36) months.